Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03696173 · ClinicalTrials.gov registry record
Safety Study of Abatacept in Rheumatoid Arthritis Participants
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 5,800
- Enrollment target
NCT03696173: Completed study, sponsored by Bristol-Myers Squibb.
NCT03696173 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 5,800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03696173 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 5,800 participants
- Enrollment target
Study Summary
A observational study to assess whether biologic disease-modifying (BDM) treatment initiation with abatacept for rheumatoid arthritis is associated with an increased risk of serious infection and cancer
Primary Outcome
With methotrexate
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,800 participants |
| Start Date | 2015-12-17 |
| Est. Completion | 2018-06-29 |
What the finished NCT03696173 record still lists
NCT03696173 is an observational study that tracks outcomes without assigning an intervention. Its 5,800 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03696173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03696173 about?
NCT03696173 is a clinical study titled "Safety Study of Abatacept in Rheumatoid Arthritis Participants". A observational study to assess whether biologic disease-modifying (BDM) treatment initiation with abatacept for rheumatoid arthritis is associated with an increased risk of serious infection and cancer
What is the current status of trial NCT03696173?
This trial is currently completed. The enrollment target is 5,800 participants. The study started on 2015-12-17. Estimated completion is 2018-06-29.
What interventions are being tested in trial NCT03696173?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03696173?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04983875 · 5,708 participants · NA
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT06627335 · 5,621 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI